Cogent Biosciences, Inc. (COGT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.42; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.9/10 and A.R:R 4.8:1 are different metrics that happen to read the same number here.)
Cogent Biosciences is a clinical-stage biotech developing precision therapies for genetically defined diseases, with bezuclastinib (CGT9486) as its lead candidate — a highly selective KIT D816V inhibitor in late-stage trials for Systemic Mastocytosis and GIST. NDAs submitted or... Read more
Sell if holding. Engine safety override at $35.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.42; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.9/10 and A.R:R 4.8:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductbezuclastinib program10-K Item 1A: 'Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.70: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 3.42; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.9/10 and A.R:R 4.8:1 are different metrics that happen to read the same number here.) Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $33.34. Score 4.8/10, moderate confidence.
Take-profit target: $47.13 (+32.0% upside). Prior stop was $33.34. Stop-loss: $33.34.
Concentration risk — Product: bezuclastinib program; Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.1), Material insider selling (4 sells, 0.25% of cap).
Cogent Biosciences, Inc. trades at a P/E of N/A (forward -52.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover COGT with a consensus score of 4.3/5. Average price target: $54.
What does Cogent Biosciences, Inc. do?Cogent Biosciences is a clinical-stage biotech developing precision therapies for genetically defined diseases, with...
Cogent Biosciences is a clinical-stage biotech developing precision therapies for genetically defined diseases, with bezuclastinib (CGT9486) as its lead candidate — a highly selective KIT D816V inhibitor in late-stage trials for Systemic Mastocytosis and GIST. NDAs submitted or planned for NonAdvSM, GIST, and AdvSM with commercial launch expected in the U.S. in the second half of 2026, pending regulatory approval.